In the first two quarters since going public, Metagenomi’s tie-up with Moderna ended, the California startup’s chief scientific officer departed and now the preclinical biotech’s pipeline has been fine-tuned.
Meanwhile, it made progress with partners Ionis and Affini-T, according to a Wednesday morning quarterly update.
The gene editing company, which was one of the few drug developers to go public before entering human trials during the market downturn, wants to offload multiple projects, it said in a second-quarter update. That includes finding a partner or licensee for its primary hyperoxaluria type 1 program and a licensee for its ex vivo cell therapy work.
Metagenomi is also ditching plans for amyotrophic lateral sclerosis following “recent peer company clinical data regarding the lack of efficacy of Ataxin-2 as a therapeutic target” for the condition. Metagenomi did not name the company. Biogen and partner Ionis said in May that they were scrapping an
